Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00894504 · ClinicalTrials.gov registry record · Phase 2

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

A Phase 2 study of Metastatic Breast Cancer, sponsored by SCRI Development Innovations.

Completed
Registry status
Phase 2
Development phase
71
Enrollment target
17
Study locations

NCT00894504 is a Phase 2 study of Metastatic Breast Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 71 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (65% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00894504, a Phase 2 study of Metastatic Breast Cancer, has completed, sponsored by SCRI Development Innovations.

COMPLETED
Registry status
Phase 2
Development phase
71 participants
Enrollment target
17
Study locations

Study Summary

In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer. In addition, to assess the efficacy of this combination, tumor tissue will be examined for the presence of various markers, including K-ras and PI3K-activating mutations, EGFR, PTEN, and p53. Correlation of tumor response with marker expression may define a patient subset that is particularly responsive to treatment with a panitumumab-containing combination.

Conditions Studied

Metastatic Breast Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Gemcitabine
  • DRUG Panitumumab

Study Locations (17)

Tennessee

  • Chattanooga Oncology Hematology Associates - Chattanooga
  • Family Cancer Center - Collierville
  • Tennessee Oncology - Nashville

Florida

  • Aventura Hospital and Medical Center - Aventura
  • Florida Cancer Specialists - Fort Myers

Maryland

  • Center for Cancer and Blood Disorders - Bethesda
  • National Capital Clinical Research Consortium - Bethesda

Missouri

  • St. Louis Cancer Care - Chesterfield
  • Research Medical Center - Kansas City

California

  • Los Robles - Thousand Oaks

Indiana

  • Providence Medical Group - Terre Haute

Kentucky

  • Norton Cancer Institute - Louisville

Nebraska

  • Nebraska Methodist Cancer Center - Omaha

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2010-02
Est. Completion 2014-09
Phase Phase 2

Sponsor

SCRI Development Innovations

146 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00894504

The ClinicalTrials.gov registry entry for NCT00894504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (65% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT00894504 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Tennessee, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT00894504 about?

NCT00894504 is a clinical study titled "Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer". In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer. In addition, to assess the efficacy of this combination, tumor tissue will be examined for the presence of ...

What is the current status of trial NCT00894504?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2010-02. Estimated completion is 2014-09.

What conditions does trial NCT00894504 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT00894504?

The interventions under investigation include: Carboplatin (DRUG), Gemcitabine (DRUG), Panitumumab (DRUG).

Who is sponsoring clinical trial NCT00894504?

This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00894504 being conducted?

This trial has 17 study locations across California, Florida, Indiana, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.